[{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"United Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase IV","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United Therapeutics \/ United Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"United Therapeutics \/ United Therapeutics"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ United Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"United Therapeutics \/ United Therapeutics"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"United Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tadalafil","moa":"Phosphodiesterase 5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ United Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"United Therapeutics \/ United Therapeutics"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"University of North Carolina","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"United Therapeutics \/ United Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"United Therapeutics \/ United Therapeutics"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"United Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Epoprostenol Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"United Therapeutics \/ United Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"United Therapeutics \/ United Therapeutics"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ralinepag","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ralinepag","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ralinepag","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ralinepag","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ralinepag","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ralinepag","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"United Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Immunology","graph2":"Phase II","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ United Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"United Therapeutics \/ United Therapeutics"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"United Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ United Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"United Therapeutics \/ United Therapeutics"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"United Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ United Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"United Therapeutics \/ United Therapeutics"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"United Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ United Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"United Therapeutics \/ United Therapeutics"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"United Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ United Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"United Therapeutics \/ United Therapeutics"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"CVie Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United Therapeutics \/ CVie Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"United Therapeutics \/ CVie Therapeutics"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"CVie Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United Therapeutics \/ CVie Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"United Therapeutics \/ CVie Therapeutics"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Lung Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United Therapeutics \/ Lung Biotechnology","highestDevelopmentStatusID":"11","companyTruncated":"United Therapeutics \/ Lung Biotechnology"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Lung Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"United Therapeutics \/ Lung Biotechnology","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Lung Biotechnology"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ United Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"United Therapeutics \/ United Therapeutics"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Yuh Chin T Huang, MD, MHS","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"United Therapeutics \/ Yuh Chin T Huang, MD, MHS","highestDevelopmentStatusID":"6","companyTruncated":"United Therapeutics \/ Yuh Chin T Huang, MD, MHS"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Treprostinil Diolamine","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Treprostinil Diolamine","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Treprostinil Diolamine","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Treprostinil Diolamine","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Treprostinil Diolamine","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Treprostinil Diolamine","moa":"Prostanoid IP receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Treprostinil Diolamine","moa":"Prostanoid IP receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Treprostinil Diolamine","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Treprostinil Diolamine","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Treprostinil Diolamine","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Treprostinil Diolamine","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Treprostinil Diolamine","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"DEKA Research & Development","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United Therapeutics \/ DEKA Research & Development","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ DEKA Research & Development"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"United Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United Therapeutics \/ United Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"United Therapeutics \/ United Therapeutics"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United Therapeutics \/ United Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ United Therapeutics"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Liquidia Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule, Powder for Inhalation","sponsorNew":"United Therapeutics \/ United Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ United Therapeutics"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Mannkind","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"United Therapeutics \/ Mannkind","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Mannkind"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Mannkind","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.10000000000000001,"dosageForm":"Powder for Inhalation","sponsorNew":"United Therapeutics \/ United Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ United Therapeutics"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Ferrer Internacional","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"United Therapeutics \/ Ferrer Internacional","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Ferrer Internacional"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"University of Pittsburgh Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ University of Pittsburgh Medical Center","highestDevelopmentStatusID":"9","companyTruncated":"United Therapeutics \/ University of Pittsburgh Medical Center"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Ferrer Internacional","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ Ferrer Internacional","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Ferrer Internacional"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"United Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0.11,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.11,"dosageForm":"Powder for Inhalation","sponsorNew":"United Therapeutics \/ United Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ United Therapeutics"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Mesenchymal-Like Adherent Stromal Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"MIRO-001 Bioengineered Liver Graft","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"5","companyTruncated":"United Therapeutics \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"MIRO-001 Bioengineered Liver Graft","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MIRO-001 Bioengineered Liver Graft","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"United Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Mirokidney","moa":"Undisclosed","graph1":"Nephrology","graph2":"Preclinical","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ United Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"United Therapeutics \/ United Therapeutics"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"United Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Mirokidney","moa":"Undisclosed","graph1":"Nephrology","graph2":"Preclinical","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ United Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"United Therapeutics \/ United Therapeutics"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"United Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Mirokidney","moa":"Undisclosed","graph1":"Nephrology","graph2":"Preclinical","graph3":"United Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ United Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"United Therapeutics \/ United Therapeutics"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"UNEX-42","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Xenokidney","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Imperial College London","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Capsaicin","moa":"Vanilloid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Patch","sponsorNew":"United Therapeutics \/ United Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"United Therapeutics \/ United Therapeutics"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"United Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"Capsaicin","moa":"Vanilloid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United Therapeutics \/ United Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"United Therapeutics \/ United Therapeutics"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Mannkind","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"United Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ United Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"United Therapeutics \/ United Therapeutics"}]
Find Clinical Drug Pipeline Developments & Deals by United Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
